Assessing the treatment of cannabidiolic acid methyl ester: a stable synthetic analogue of cannabidiolic acid on c‑Fos and NeuN expression in the hypothalamus of rats Eric Murillo‑Rodríguez, Diana Millán‑Aldaco, Gloria Arankowsky‑Sandoval, Tetsuya Yamamoto, Roger G. Pertwee, Linda Parker and Raphael Mechoulam Abstract Background : Cannabidiol (CBD), the non-psychotropic compound from Cannabis sativa, shows positive results on controlling several health disturbances; however, comparable data regarding additional chemical from C. sativa, such as cannabidiolic acid (CBDA), is scarce due to its instability. To address this limitation, a stable CBDA analogue, CBDA methyl ester (HU-580), was synthetized and showed CBDA-like effects. Recently, we described that HU-580 increased [...]
Lire la suiteCannabidiol attenuates haloperidol-induced catalepsy and c-Fos protein expression in the dorsolateral striatum via 5-HT1A receptors in mice Andreza B. Sonego; Felipe V. Gomes; Elaine A. Del Bel; Francisco S. Guimaraes Behavioural Brain Research, 2016, 21. Doi : 10.1016/j.bbr.2016.04.042 Highlights Cannabidiol (CBD) attenuated haloperidol-induced catalepsy. CBD reduced c-Fos protein expression in the dorsal striatum induced by haloperidol. CBD effects were blocked by 5-HT1A receptor antagonist. Abstract Cannabidiol (CBD) is a major non-psychoactive compound from Cannabis sativa plant. Given that CBD reduces psychotic symptoms without inducing extrapyramidal motor side-effects in animal models and schizophrenia patients, it has been proposed to act as an atypical antipsychotic. In addition, CBD [...]
Lire la suiteNonlinear Disposition and Metabolic Interactions of Cannabidiol Through CYP3A Inhibition In Vivo in Rats Michiru Nagao, Yukako Nakano, Masataka Tajima, Erika Sugiyama, Vilasinee Hirunpanich Sato, Makoto Inada, and Hitoshi Sato Cannabis and Cannabinoid Research, 2020, Volume X, Number X, 1-8. DOI: 10.1089/can.2019.0098 Abstract Introduction : Cannabidiol (CBD) is known to affect the pharmacokinetics of other drugs through metabolic inhibition of CYP2C19 and CYP3A4. However, there is a lack of in vivo evidence for such drug interactions. Therefore, we investigated the saturability of CBD metabolism and CBD-drug interactions through inhibition of CYP3A in vivo. Materials and Methods : A nanoemulsion formulation of CBD (CBD-NE) was orally administered to [...]
Lire la suiteCannabidiol Is a Potential Therapeutic for the Affective-Motivational Dimension of Incision Pain in Rats Karina Genaro, Débora Fabris, Ana L. F. Arantes, Antônio W. Zuardi, José A. S. Crippa and Wiliam A. Prado Frontiers in Pharmacology, June 2017 | Volume 8 | Article 391 doi : 10.3389/fphar.2017.00391 Background : Pain involves different brain regions and is critically determined by emotional processing. Among other areas, the rostral anterior cingulate cortex (rACC) is implicated in the processing of affective pain. Drugs that interfere with the endocannabinoid system are alternatives for the management of clinical pain. Cannabidiol (CBD), a phytocannabinoid found in Cannabis sativa, has been utilized [...]
Lire la suiteHippocampal Neurotoxicity of D9-Tetrahydrocannabinol Guy Chiu-Kai Chan, Thomas R. Hinds, Soren Impey, and Daniel R. Storm The Journal of Neuroscience, 1998, 18, (14), 5322–5332 Marijuana consumption elicits diverse physiological and psychological effects in humans, including memory loss. Here we report that D9-tetrahydrocannabinol (THC), the major psychoactive component of marijuana, is toxic for hippocampal neurons. Treatment of cultured neurons or hippocampal slices with THC caused shrinkage of neuronal cell bodies and nuclei as well as genomic DNA strand breaks, hallmarks of neuronal apoptosis. Neuron death induced by THC was inhibited by nonsteroidal anti-inflammatory drugs, including indomethacin and aspirin, as well as vitamin E and [...]
Lire la suite